ATEZOTRIBE

NCT03721653 📎

Regimen

Experimental
Atezolizumab + FOLFOXIRI + bevacizumab
Control
Placebo + FOLFOXIRI + bevacizumab

Population

Metastatic CRC, 1L, unselected by MMR/MSI status; key subgroup analysis by pMMR/MSS vs dMMR/MSI-H.

Key finding

Overall: atezolizumab + FOLFOXIRI+bev vs FOLFOXIRI+bev: median PFS 13.1 vs 11.5 months (HR 0.69 [80% CI 0.56–0.85]; p=0.012); adjusted HR 0.70; dMMR subgroup (n=29): more pronounced benefit; MSS subgroup: modest/non-significant benefit; grade 3–4 neutropenia 42% vs 36%; 2 treatment-related deaths in atezolizumab arm.

Source: PMID 35636444

Timeline